I am looking at the sunrise trial on drug trials dot gov. Do you know why all clinical sites that take patients are Peregrine and why they don't use universities and large clinics to collect patients?
The biggest threat to provenge in the next two years is prostvac by Novartis which recently filled its patient rolls. I suspect the survival signal will be lost if the patient subsequently put on standard of care zytiga or xtandi and prostvac will likely fail.
CAR-t hype right now is siphoning investment dollars from all biotech sectors. GVHD symptoms will likely kill many patients, but at this juncture NIH is fueling the hype that those sideeffects are treatable.